Anti-Idiotypic Antibodies – Supporting the Development of Human Antibody Therapeutics & Preclinical Research

HuCAL® anti-idiotypic antibodies help to overcome the problems faced in detecting low levels of human antibody drugs in patient serum. Developed to be highly specific and sensitive, our anti-idiotypic antibodies are ideal for developing pharmacokinetic (PK) and immunogenicity (IR) assays.

  • Highly specific, fully-human antibodies
  • Unlimited & secure supply

Development of Recombinant Anti-Idiotypic Antibodies for PK/PD and Immunogenicity Assays

This video content presented here requires JavaScript to be enabled and the latest version of the Adobe Flash Player. If you are using a browser with JavaScript disabled please enable it now. Otherwise, please update your version of the free Adobe Flash Player by downloading here.

Ready-made antibodies: 

 Custom anti-idiotypic antibody services are also available to generate an antibody for your desired specificity

* Antibodies currently in development.  Anti-Remicade (infliximab) antibodies are not available in the USA

HuCAL® is a registered trademark of MorphoSys AG. Rituxan® is a registered trademark of Biogen Idec, Inc. USA. Remicade® is a registered trademark of Janssen Biotech, Inc. USA. Campath® is a registered trademark of Genzyme Corporation. Herceptin® is a registered trademark of Genentech, Inc. USA. Avastin® is a registered trademark of Genentech, Inc. USA. Stelara® is a registered trademark of Janssen Biotech, Inc. USA. HUMIRA® is a registered trademark of Abbott Laboratories.